ESOPHAGEAL CANCER

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung, esophageal, or skin cancer that has spread or can't be removed. The main goals are to check safety, find the right dose, and see if it helps control the cancer. Participants receive the drug i…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive solid tumors that have spread and are not responding to other treatments. About 100 people will be followed to see if their tumors shrink and how long that lasts. The goal is to provide a trea…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This early-stage study tests a new drug called SH009 in about 150 people with advanced solid tumors (like liver, lung, or breast cancer) that have not responded to standard treatments. The main goal is to see if the drug is safe and can shrink tumors. Researchers will also measur…

This early-stage study tests a new drug called PF-08046876 in people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. The drug is designed to stick to cancer cells and kill them directly. The main goals are to check safety, find the best dose, an…

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancer that has spread. The goal is to see if these drug combinations can shrink tumors or slow disease progression. About 376 adults aged 18 to 75 will participate, and the…

This early-phase study tests a new drug called BL-M17D1 in people with advanced HER2-positive or low-HER2 gastrointestinal cancers and other solid tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 20 adults will take part, …

This early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…

This study tests whether adding a precise, high-dose internal radiation treatment (brachytherapy) after standard external radiation, chemotherapy, and the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back. About 60 adults with advanced esophageal sq…

This study is testing whether adding two targeted drugs, pembrolizumab and trastuzumab, to standard chemotherapy can improve outcomes for people with HER2+ esophageal or stomach cancer that can be surgically removed. The treatment is given before surgery to shrink the tumor. The …

This early-stage study tests a new treatment using a patient's own immune cells, engineered to target a protein called CEA found on certain cancer cells. It is for adults with advanced lung, stomach, colon, rectal, esophageal, or pancreatic cancer who have not responded to standa…

This study is testing whether a combination of three treatments—an immunotherapy drug (bemosubaiabimab), a targeted therapy (anlotinib), and standard chemoradiation—can shrink tumors in people with esophageal cancer that has spread to a limited number of other sites (oligometasta…

This study tests whether adding low-dose or standard radiotherapy to the usual immunotherapy and chemotherapy can help control metastatic esophageal squamous cell carcinoma. About 100 adults with untreated, advanced cancer will be enrolled. The goal is to see if the combination i…

This study tests a new drug (sonesitatug vedotin) plus chemotherapy, with or without another drug (rilvegostomig), in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. About 2,130 participants…

This early-phase trial tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part.

This study tests whether giving two different chemotherapy and radiation regimens one after the other (total neoadjuvant therapy) works better than standard treatment for patients with esophageal cancer that has spread to nearby lymph nodes. About 216 adults with resectable cance…

This study tests whether adding targeted radiation and an immunotherapy drug (durvalumab) to a short course of chemotherapy and radiation can help control advanced esophageal cancer and relieve trouble swallowing. About 54 adults with cancer that has spread to a few other spots o…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer who…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has gotten worse after one prior treatment. About 210 participants will receive either an experimental antibody-drug combo plus standard chemo, or sta…

This study tests a preventive vacuum treatment placed inside the body after esophageal cancer surgery to stop leaks where the esophagus is reconnected to the stomach. About 44 adults having minimally invasive surgery for esophageal cancer will receive this therapy. The goal is to…

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug c…

This study tests a new treatment called EBNK-001, which uses donor natural killer (NK) cells to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive the NK cells along with ch…

This study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. Participants first receive a combination of immunotherapy and chemotherapy, followed by standard chemoradiation. Throughout treatment, doctors will monitor tiny bits of t…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This study tests a new combination treatment for people with advanced esophageal cancer that cannot be removed by surgery. The treatment uses a virus that attacks cancer cells, along with chemotherapy and an immunotherapy drug. The goal is to shrink the tumor enough so that surge…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely treat advanced stomach, gastroesophageal junction, or esophageal cancer that has not spread to other organs. About 160 adults whose cancer is HER2-negat…

This study looks at people with esophageal or stomach cancer that has spread to only a few places (oligometastases). All participants get 4 months of standard drug therapy, then are randomly assigned to either have local treatment (surgery or radiation) right away or after anothe…

This study tests an experimental drug called TQB6411 in people with advanced esophageal cancer that has returned or spread and no longer responds to standard immunotherapy and chemotherapy. The trial has two parts: first, finding a safe dose, then checking if the drug can shrink …

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This study is for people with advanced esophageal cancer that cannot be removed by surgery. Researchers want to see if starting with a short course of immunotherapy plus chemotherapy can help guide the next steps. Based on how the tumor responds, patients will get either the same…

This early-phase trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study aims to find the safest dose and check if the com…

This early-phase trial tests TJ101, an experimental antibody-drug conjugate, in adults with advanced solid tumors (lung, prostate, esophageal, and others) who have no standard treatment options left. The main goals are to find a safe dose and see if the drug can shrink tumors. Ab…

This study aims to find the best treatment before surgery for esophageal cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy in 2000 adults with stage I-IVa disease. The goal is to improve survival and reduce side effects.

This study looks at two different treatments for people with a type of esophageal cancer that shrank after initial drug therapy. Half will get standard surgery, the other half will get radiation and chemo instead. The goal is to see if avoiding surgery is just as effective and he…

This study tests a new drug called HLX43 in people with advanced esophageal cancer that did not get better with or could not tolerate standard first treatment. The drug works by targeting a protein on cancer cells to deliver a toxin directly. About 72 adults aged 18 to 75 will ta…

This study tests whether adding the immunotherapy drug iparomlimab after standard chemoradiation can help older adults (70+) with inoperable esophageal cancer live longer without their cancer growing. About 52 participants will receive the drug for one year after initial treatmen…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study tests whether combining the immunotherapy drug camrelizumab with chemotherapy can shrink esophageal cancer enough to avoid surgery and preserve the organ. About 283 adults with resectable esophageal squamous cell cancer will receive the treatment before any surgery dec…

This phase 3 trial tests whether adding two drugs—toripalimab (an immunotherapy) and capecitabine (a chemotherapy pill)—after standard chemoradiation can help prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer that hasn't spread after ini…

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days…

This study tests an FDA-approved drug called CYTALUX (pafolacianine) that makes cancer cells glow under a special camera during surgery. About 50 adults with certain gastrointestinal or gynecologic cancers will receive the drug before their operation. The goal is to see if the gl…

This study is testing whether a special PET scan called 18F-AraG can find esophageal tumors and predict how well they respond to chemoradiation. About 60 adults with untreated, locally advanced esophageal cancer will receive the scan before and during treatment. The goal is to im…

This study is testing a new type of PET scan that looks for a protein called CLDN18.2 on cancer cells. It includes about 56 adults with stomach, pancreatic, bile duct, or esophageal cancers, plus some healthy volunteers. The goal is to see if this scan can accurately find tumors …

This study is testing a simple, non-invasive device called EsophaCap — a sponge in a capsule that you swallow. It collects cells from the food pipe and stomach to look for DNA changes that might signal early cancer or pre-cancer conditions like Barrett's esophagus. The goal is to…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including breast, lung, and colon cancer. Researchers want to see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before symptoms appear. About …

This study tests a new type of PET scan called [18F]FAPI-74 to see if it can better find cancer that has spread in adults with stomach or esophageal cancer. About 200 participants will get one dose of the scan tracer and be followed for up to 3 months. The goal is to see if this …

This study tests whether a dye called CYTALUX™, given before surgery, can help surgeons see cancer tissue in real time using a special camera. It includes 15 adults with stomach, esophagus, or appendix cancer who are already scheduled for surgery. The goal is to improve how compl…

This study is testing whether certain chemicals in a person's breath and blood can help detect early-stage gastro-esophageal cancer. Researchers will compare samples from 1000 people, including those with cancer, those with a pre-cancer condition called Barrett's esophagus, and h…

This study is testing a new imaging system that uses a special dye to make cancer cells glow, helping surgeons see and remove them more completely. About 66 adults with colorectal, pancreatic, esophageal, or gastric cancer will take part before their scheduled surgery. The goal i…

This pilot study tests if brodalumab, a drug approved for autoimmune diseases, can safely reduce severe side effects caused by cancer immunotherapy. About 11 adults with various solid tumors who have immune-related side effects will receive brodalumab. The goal is to see if it lo…

This study is for people with advanced esophageal cancer that cannot be cured. It tests whether adding two chemotherapy drugs (carboplatin and paclitaxel) to standard radiation therapy can better relieve trouble swallowing and improve quality of life. About 50 participants will r…

This study tests a personalized program of diet, exercise, supplements, and stress management for people undergoing surgery for lung, stomach, or esophageal cancer. The goal is to see if this approach improves quality of life, reduces complications, and helps patients feel better…

This study tests whether using a breathing machine (CPAP or BiPAP) can reduce tumor movement during radiation therapy for people with advanced lung cancer, esophageal cancer, or lymphoma. The goal is to see if these devices help keep the tumor still, which could make treatment mo…

This study tests whether a tailored palliative care plan can help people with advanced esophageal cancer live longer and feel better. About 624 adults will receive either standard comfort care or a personalized version that adjusts to their needs. All participants will complete s…

This study tests whether a high-flow nasal cannula (a device that delivers warm, moist oxygen through the nose) can prevent low oxygen levels during sedated gastrointestinal endoscopy in people at high risk for obstructive sleep apnea. About 600 adults with a STOP-Bang score of 5…

This study looks at whether a short exercise program before surgery is practical and helpful for people with esophageal cancer. Twenty patients preparing for tumor removal will try the program. Researchers will track how many complete the program and any health improvements.

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen support, airway management, and monitoring to reduce the risk of low oxygen levels (hypoxia), a common com…

This study tests whether a new device that combines an airway tube, oxygen, and monitoring can reduce low oxygen levels during sedated endoscopy in people with severe obesity (BMI 35 or higher). About 410 participants will be randomly assigned to receive either standard high-flow…

This study looks at whether giving a longer infusion of the chemotherapy drug paclitaxel to cancer patients with low muscle mass can make drug levels in their blood more like those in patients with normal muscle mass. About 22 women with breast, stomach, or esophageal cancer will…

This study collects tissue and blood samples from people with stomach or esophageal cancer, as well as those at high inherited risk, to learn how genes and proteins contribute to these cancers. Researchers aim to better understand the disease, not to test a new treatment. About 1…

This study tracks how often esophageal cancer spreads to a specific lymph node near the windpipe and what factors increase that risk. About 1,852 participants with esophageal cancer will be observed during surgery. The goal is to better understand the disease, not to test a new t…

This study collects tissue, blood, urine, and stool samples from 5,000 people undergoing colonoscopy or endoscopy, including those with GI cancers, polyps, or inflammatory bowel disease, as well as healthy volunteers. Researchers aim to find new biomarkers that could lead to earl…

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. Over 2,200 adults a…

This study looks at whether changes in DNA markers in the blood can show how well esophageal cancer responds to treatment. Researchers will compare these markers with standard scans and tumor tests in 300 adults. The goal is to find a faster, less invasive way to guide treatment …

This study looks at whether a program of exercise and nutrition supplements before esophageal cancer surgery is practical and helpful for patients. About 20 adults scheduled for surgery will either receive the program or standard care. Researchers will track how many people join,…

This study aims to find markers in blood and tissue that could signal a higher risk of developing esophageal cancer. Researchers will collect medical history and samples from up to 7,000 people with esophageal disorders like GERD or Barrett's esophagus. The goal is to improve ear…

This study tracks how often esophageal cancer spreads to lymph nodes near the windpipe (subcarinal area) in 1,100 patients. Researchers will also look for factors that raise the risk of this spread and measure survival. The goal is to help doctors decide on better treatment strat…

This study is testing whether an artificial intelligence (AI) system can predict how well esophageal cancer will respond to treatment and how risky the disease is for each patient. The AI will analyze medical images, genetic information, and other health data from 1,500 participa…

This study looks at whether a specific gene, ALDH2, which helps break down alcohol, is linked to how long people with esophageal cancer survive. Researchers will follow 700 patients for up to 150 months to track survival. The goal is to understand how genetic differences might in…

This study looks at genetic differences between the original stomach or esophageal cancer and any brain tumors that spread from it. Researchers will analyze stored tissue samples from 30 patients to see if key markers like HER2, MSI, PD-L1, and CLDN18.2 change. The goal is to und…

This study collects samples from 320 people, including those with solid cancers and those undergoing lung cancer screening, to detect tumor cells and DNA in blood, urine, and bone marrow. The goal is to learn more about how cancer spreads and to improve early detection and person…

This study enrolls 620 adults with solid cancers (lung, esophageal, stomach, pancreatic, liver, colorectal) to collect blood, urine, and bone marrow samples. Researchers will measure circulating tumor cells and DNA to see how they relate to cancer recurrence and survival. The goa…

This study is tracking 3,500 people who have surgery for esophageal cancer to compare how well they recover after a minimally invasive procedure versus traditional open surgery. Researchers will measure quality of life, physical function, and mental health using questionnaires ov…

This study is collecting information from 8,000 cancer patients treated with a special machine called the MR-Linac, which combines an MRI scanner with a radiation therapy device. The goal is to see how well this technology works for different cancers, including breast, prostate, …

This study looks at sputum and tissue samples from 700 people with or without precancerous changes in the airways. The goal is to find biomarkers—biological clues—that may help detect lung, head and neck, or esophageal cancer earlier. Participants provide samples during routine p…

This study is testing a new questionnaire to better understand and track symptoms in people with upper digestive diseases or who have had esophageal surgery. Researchers will ask 1000 patients to complete the survey at different times. The goal is to create a standard tool that h…

This study is creating a simple tool to predict which patients might have food or liquid left in their stomach during a sedated gastroscopy (a scope exam of the stomach). Having stomach contents increases the risk of serious complications like choking. Researchers will study 5,00…

This study looks at how radiation treatment for esophageal cancer affects the body's ability to respond to the pneumonia vaccine. Researchers will measure antibody levels in 80 patients before and after vaccination. The goal is to understand if low white blood cell counts caused …

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the edge of the removed tissue (called the margin) relates to how long patients live and whether the cancer comes back. No new treatments or procedures are gi…

This study looks at past medical records to see if people with esophageal cancer do better at hospitals that treat many cases versus those that treat fewer. Researchers will compare survival rates between high-volume (more than 5 surgeries per year) and low-volume (less than 5 su…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning sooner than standard scans. Researchers will follow 100 people with various solid tumors to see if early detection leads to better treatment options. The goal is to improve how w…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to the cancer care team helps people aged 70 and older with gastrointestinal cancers. Researchers want to see if this approach is practical and if it reduces unplanned hospital v…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if chan…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…